Barclays Lowers Hinge Health (NYSE:HNGE) Price Target to $52.00

Hinge Health (NYSE:HNGE) had its price target lowered by stock analysts at Barclays from $60.00 to $52.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Barclays‘s price target indicates a potential upside of 31.51% from the stock’s current price.

HNGE has been the subject of a number of other reports. KeyCorp lowered their target price on Hinge Health from $72.00 to $70.00 and set an “overweight” rating for the company in a report on Thursday, January 8th. Piper Sandler dropped their price objective on shares of Hinge Health from $71.00 to $60.00 and set an “overweight” rating for the company in a report on Friday, January 9th. Weiss Ratings reiterated a “sell (d)” rating on shares of Hinge Health in a report on Thursday, January 22nd. Needham & Company LLC reissued a “buy” rating and issued a $59.00 price target on shares of Hinge Health in a research report on Wednesday. Finally, Wells Fargo & Company initiated coverage on shares of Hinge Health in a research note on Thursday, January 8th. They issued an “overweight” rating and a $68.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Hinge Health currently has an average rating of “Moderate Buy” and an average target price of $57.71.

Hinge Health Stock Up 2.0%

HNGE opened at $39.54 on Wednesday. Hinge Health has a 52 week low of $30.08 and a 52 week high of $62.18. The business has a fifty day simple moving average of $43.76 and a 200-day simple moving average of $48.80. The firm has a market cap of $3.11 billion and a P/E ratio of -3.01.

Hinge Health announced that its Board of Directors has authorized a stock buyback plan on Wednesday, November 12th that permits the company to repurchase $250.00 million in outstanding shares. This repurchase authorization permits the company to reacquire up to 7.2% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

Insider Activity at Hinge Health

In other Hinge Health news, major shareholder Bessemer Venture Partners X. L. sold 725,000 shares of the stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $40.05, for a total value of $29,036,250.00. Following the sale, the insider directly owned 3,383,707 shares of the company’s stock, valued at approximately $135,517,465.35. This represents a 17.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO James Budge sold 44,589 shares of Hinge Health stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $47.47, for a total transaction of $2,116,639.83. Following the sale, the chief financial officer directly owned 479,878 shares of the company’s stock, valued at approximately $22,779,808.66. This trade represents a 8.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 2,805,105 shares of company stock worth $128,216,614 over the last ninety days.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in HNGE. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Hinge Health in the 3rd quarter valued at about $37,000. First Horizon Corp increased its stake in Hinge Health by 163.9% in the fourth quarter. First Horizon Corp now owns 855 shares of the company’s stock valued at $40,000 after purchasing an additional 531 shares during the last quarter. Montag A & Associates Inc. acquired a new stake in Hinge Health during the second quarter worth approximately $41,000. High Point Wealth Management LLC purchased a new stake in shares of Hinge Health during the 4th quarter worth approximately $46,000. Finally, SBI Securities Co. Ltd. acquired a new position in shares of Hinge Health in the 2nd quarter valued at $48,000.

Hinge Health News Roundup

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Q4 beat — Hinge reported a Q4 revenue surge and earnings that materially exceeded estimates, driving investor optimism about near-term growth. Investing.com: Q4 earnings
• Positive Sentiment: 2026 guidance & AI investments — Management outlined a 2026 revenue target (~$732M) and a ~25% revenue growth target, citing expansion of AI-driven care that supports the stronger outlook. FierceHealthcare: 2026 revenue projection
• Positive Sentiment: Analyst support — Citizens JMP reaffirmed a “market outperform” rating and set a $65 price target, signaling substantial upside vs. current levels and backing the post-earnings enthusiasm. Benzinga: Citizens JMP
• Positive Sentiment: More buy-side reinforcement — Needham reiterated a “buy” rating with a $59 target, adding to constructive analyst commentary. TickerReport: Needham
• Neutral Sentiment: Investor materials available — The company published its Q4 earnings presentation and call transcript for detailed checks on margin trends, unit economics and AI investment cadence. Useful for investors wanting to validate guidance assumptions. Seeking Alpha: Earnings presentation
• Neutral Sentiment: Price action / volume — The stock posted a sizable intraday rally with volume well above average, reflecting short-covering and fresh buyer interest; this can amplify volatility in either direction. MSN: Intraday move
• Negative Sentiment: Mixed analyst actions — Barclays lowered its price target from $60 to $52 (still “overweight”), which trims some upside vs. the more bullish targets and highlights lingering analyst caution about sustained margins or execution risk. Benzinga: Barclays
• Negative Sentiment: Profitability risk — Despite the revenue beat, Hinge remains unprofitable (negative P/E), so investors should watch whether revenue growth translates into sustainable margins and cash flow over the next several quarters.

Hinge Health Company Profile

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.